{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T14:47:55Z","timestamp":1792248475012,"version":"4.4.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13555-025-01609-6","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:57:13Z","timestamp":1765177033000},"page":"605-616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Post Hoc Analysis of Atopic Dermatitis of the Head and Neck and Other Body Regions from the Amlitelimab STREAM-AD Phase\u00a02b Study"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct05131477","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5573-1754","authenticated-orcid":false,"given":"Adam","family":"Reich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3944-252X","authenticated-orcid":false,"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7510-9428","authenticated-orcid":false,"given":"Vivian Y.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3498-2482","authenticated-orcid":false,"given":"Norito","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9163-5463","authenticated-orcid":false,"given":"Charles","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8809-8564","authenticated-orcid":false,"given":"Xinghua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2479-1076","authenticated-orcid":false,"given":"Nicole M.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4563-8927","authenticated-orcid":false,"given":"Charlotte","family":"Bernigaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6700-9171","authenticated-orcid":false,"given":"Kassim","family":"Rahawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"issue":"10247","key":"1609_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360.","journal-title":"Lancet"},{"issue":"5","key":"1609_CR2","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","volume":"132","author":"JI Silverberg","year":"2013","unstructured":"Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1609_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"1609_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/DER.0000000000000895","volume":"33","author":"JM Hanifin","year":"2022","unstructured":"Hanifin JM, Baghoomian W, Grinich E, et al. The Eczema Area and Severity Index-a practical guide. Dermatitis. 2022;33(3):187\u201392.","journal-title":"Dermatitis"},{"issue":"7","key":"1609_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/14712598.2023.2224499","volume":"23","author":"N Gori","year":"2023","unstructured":"Gori N, Ippoliti E, Peris K, Chiricozzi A. Head and neck atopic dermatitis: still a challenging manifestation in the biologic era. Expert Opin Biol Ther. 2023;23(7):575\u20137.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"1609_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/DER.0000000000000590","volume":"31","author":"J Jaros","year":"2020","unstructured":"Jaros J, Hendricks AJ, Shi VY, Lio PA. A practical approach to recalcitrant face and neck dermatitis in atopic dermatitis. Dermatitis. 2020;31(3):169\u201377.","journal-title":"Dermatitis"},{"issue":"4","key":"1609_CR7","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/bjd.18730","volume":"183","author":"LEM de Wijs","year":"2020","unstructured":"de Wijs LEM, Nguyen NT, Kunkeler ACM, et al. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol. 2020;183(4):745\u20139.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1609_CR8","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/jamadermatol.2019.2613","volume":"155","author":"A Soria","year":"2019","unstructured":"Soria A, Du-Thanh A, Seneschal J, et al. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155(11):1312\u20135.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"1609_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/cells13070587","volume":"13","author":"K Sadrolashrafi","year":"2024","unstructured":"Sadrolashrafi K, Guo L, Kikuchi R, et al. An OX-tra\u2019ordinary tale: the role of OX40 and OX40L in atopic dermatitis. Cells. 2024;13(7):587.","journal-title":"Cells"},{"issue":"5","key":"1609_CR10","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/cpt.2539","volume":"111","author":"M Saghari","year":"2022","unstructured":"Saghari M, Gal P, Gilbert S, et al. OX40L inhibition suppresses KLH-driven immune responses in healthy volunteers: a randomized controlled trial demonstrating proof-of-pharmacology for KY1005. Clin Pharmacol Ther. 2022;111(5):1121\u201332.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1609_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/bjd\/ljad240","volume":"189","author":"S Weidinger","year":"2023","unstructured":"Weidinger S, Bieber T, Cork MJ, et al. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase\u00a0IIa randomized placebo-controlled trial. Br J Dermatol. 2023;189(5):531\u20139.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1609_CR12","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jaci.2024.10.031","volume":"155","author":"S Weidinger","year":"2025","unstructured":"Weidinger S, Blauvelt A, Papp KA, et al. Phase\u00a02b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2025;155(4):1264\u201375.","journal-title":"J Allergy Clin Immunol"},{"key":"1609_CR13","volume-title":"User\u2019s guide","author":"SAS\/STAT\u00ae","year":"2023","unstructured":"SAS\/STAT\u00ae. User\u2019s guide, vol. 15.3. Cary: SAS Institute Inc.; 2023."},{"issue":"4","key":"1609_CR14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40257-025-00931-1","volume":"26","author":"R Chovatiya","year":"2025","unstructured":"Chovatiya R, Ribero S, Wollenberg A, et al. Long-term disease control and minimal disease activity of head and neck atopic dermatitis in patients treated with tralokinumab up to 4\u00a0years. Am J Clin Dermatol. 2025;26(4):587\u2013601.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1609_CR15","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s13555-024-01158-4","volume":"14","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, de Bruin-Weller M, Hong HC, et al. Lebrikizumab provides rapid clinical responses across all Eczema Area and Severity Index body regions and clinical signs in adolescents and adults with moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2024;14(5):1145\u201360.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10372","key":"1609_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","volume":"401","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Simpson EL, Reich K, et al. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase\u00a02b study. Lancet. 2023;401(10372):204\u201314.","journal-title":"Lancet"},{"issue":"10","key":"1609_CR17","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00403-024-03426-x","volume":"316","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Esfandiari E, Mano H, et al. Durable improvements in atopic dermatitis in the head and neck and across other anatomic regions with rocatinlimab. Arch Dermatol Res. 2024;316(10):747.","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"1609_CR18","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1038\/s41467-024-46540-0","volume":"15","author":"C Bangert","year":"2024","unstructured":"Bangert C, Alkon N, Chennareddy S, et al. Dupilumab-associated head and neck dermatitis shows a pronounced type\u00a022 immune signature mediated by oligoclonally expanded T\u00a0cells. Nat Commun. 2024;15(1):2839.","journal-title":"Nat Commun"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01609-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01609-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01609-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:40:10Z","timestamp":1770190810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01609-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1609"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01609-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Adam Reich serves as consultant or speaker for AbbVie, Bioderma, Bristol-Myers Squibb, Celgene, Chema Elektromet, Eli Lilly, Galderma, Janssen, LEO Pharma, Medac, Menlo Therapeutics, Novartis, Pierre-Fabre, Sandoz, and Trevi; and principal investigator or sub-investigator in clinical trials sponsored by AbbVie, Argenx, Corbus, Drug Delivery Solutions Ltd., Eli Lilly, Galderma, Genentech, Janssen, Kymab Ltd (a Sanofi company), LEO Pharma, Menlo Therapeutics, MetrioPharm, MSD, Novartis, Pfizer, Trevi, and Viela Bio. Adam Reich is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Adam Reich was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Stephan Weidinger has received institutional research grants from LEO Pharma, Pfizer, and Sanofi Deutschland GmbH; has consulted for AbbVie, Almirall, Boehringer Ingelheim, Eli Lilly, Galderma, GSK, Kymab (a Sanofi company), LEO Pharma, Novartis, Pfizer, Regeneron, and Sanofi Genzyme; has lectured at educational events sponsored by AbbVie, Almirall, Galderma, LEO Pharma, Novartis, Pfizer, Regeneron, and Sanofi Genzyme; and is involved in performing clinical trials with many pharmaceutical companies that manufacture drugs used for the treatment of psoriasis and atopic dermatitis. Vivian Y. Shi is on the board of directors for the Hidradenitis Suppurativa Foundation; is an adviser for the National Eczema Association; is a stock shareholder of LearnHealth; and has served as an advisory board member, an investigator, speaker for and\/or has received research funding from AbbVie, Almirall, Altus Lab\/CQuell, Alumis, Aristea Therapeutics, Bain Capital, Boehringer Ingelheim, Burt\u2019s Bees, Dermira, Eli Lilly, Galderma, Genentech, Genzyme (a Sanofi company), GPSKIN, Incyte, Kiniksa Pharmaceuticals, LEO Pharma, Menlo Therapeutics, MyOr Diagnostics, Novartis, Pfizer, Polyfins Technology, Regeneron Pharmaceuticals, Skin Actives Scientific, Sun Pharma, Target PharmaSolutions, and UCB. Norito Katoh has served as a speaker\/consultant for AbbVie, Eli Lilly Japan, Maruho, Otsuka Pharmaceutical, and Sanofi; and has received grants as an investigator from LEO Pharma, Maruho, and Sun Pharmaceutical Industries. Andrew Blauvelt has served as a speaker (received honoraria) for Almirall, Eli Lilly, Sanofi, and UCB; has served as a scientific adviser (received honoraria) for AbbVie, Almirall, Alumis, Amgen, AnaptysBio, Apogee, Arcutis, Astria, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Corvus, Dermavant, Eli Lilly, Galderma, GlaxoSmithKline, Immunovant, Incyte, IQVIA, Janssen, LEO, Lipidio, Merck, Novartis, Oruka, Paragon, Pfizer, Rani Therapeutics, Regeneron, Sanofi, Spherix Global Insights, Sun Pharma, Syncona, Takeda, UCB, Union, and Zai Lab; has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Almirall, Alumis, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Galderma, Incyte, Janssen, LEO, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, and UCB; and owns stock in Lipidio and Oruka. Charles Lynde serves as a principal investigator and\/or consultant for AbbVie, Acelyrin, Actelion, Akros, Amgen, Anacor, Aralez Pharmaceuticals, Arcutis, Astellas, Avillion, Bausch Health (Valeant), Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Coherus, Dermavant, Dermira, Eli Lilly, Galderma, Gilead, GSK, Incyte, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Meiji Seika Pharma, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Sun Pharma, Takeda, and UCB. Xinghua Gao has received personal fees from advising, consulting, and lecturing for Eli Lilly, GSK, Janssen, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron, and Sanofi; is\/has been a consultant\/advisory board member for AbbVie, Boehringer Ingelheim, Novartis, Pfizer, and Sanofi; and is\/has been an investigator for AbbVie, AstraZeneca, BMS, Eli Lilly, Huaren, Beijing Jialin, LEO Pharma, Pfizer, Beijing Puqi, and Sanofi. Nicole M. Armstrong, Charlotte Bernigaud, and Kassim Rahawi are employees of Sanofi and may or may not hold stock or stock options in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"STREAM-AD was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines. The study protocol and informed consent form were reviewed and approved by institutional ethics committees and review boards at each site, and written informed consent was obtained from all patients before participation [\n                      \n                      ].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}